echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > To Yu Kanghong, Qilu Huahai stirred up 1 billion spiritual tantrums.

    To Yu Kanghong, Qilu Huahai stirred up 1 billion spiritual tantrums.

    • Last Update: 2020-10-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Pharmaceutical network October 14 days ago, CDE official website shows that Zhejiang Huahai Pharmaceuticals' Alipazine tablet imitation 3 types of listing applications were accepted.
    meters of intranet data show that in recent years, China's public medical institutions terminal sales of alecolyte tablets grew rapidly, in 2018 after breaking the 1 billion yuan mark, in 2019 to a new high, of which, Chengdu Kanghong Pharmaceuticals market share is the largest, accounting for nearly 50%.
    , the only manufacturers of aluminium-ion tablets are Chengdu Kanghong Pharmaceuticals and Qilu Pharmaceuticals.
    In recent years, the sales of end-level alipasium tablets in China's public medical institutions (units: 100 million yuan) Source: Mi-Net China's public medical institutions terminal competition pattern Alipazole tablets are the third generation of antipsychotic drugs. according to
    meters of intranet data, in recent years, China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal sales of alecolytic tablets grew rapidly, in 2018 after breaking the 1 billion yuan mark, in 2019 to a new high, of which Chengdu Kanghong Pharmaceutical market share is the largest, accounting for nearly 50%.
    Source: Minet MED2.0 China Drug Review Database At present, the domestic market approved arithpenic tablets have two kinds of alecolyxone tablets and arithpenia tablets, while the alecolyxone chip production enterprises only Chengdu Kanghong Pharmaceuticals and Qilu Pharmaceutical two.
    addition, Zhejiang Huahai Pharmaceuticals, Guangdong Dongsan Pharmaceuticals, Dongguan Yang Zhikang Pharmaceuticals to copy 3 categories of submitted applications for listing, in the review and approval (in the drug review center).
    source: CDE official website, Mienet database.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.